BiotechTube
Keltic Pharma Therapeutics

Keltic Pharma Therapeutics

Dublin, Ireland· Est.
keltic-pharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Keltic Pharma Therapeutics is a private, preclinical-stage biotech company developing a proprietary drug discovery platform called PEPSMOL©. This platform aims to create 'synthetic biologics' to target hard-to-drug GPCRs, with initial in-house programs targeting severe asthma, malaria, Alzheimer's disease, and schizophrenia. The company, founded by three renowned University of Glasgow professors, is pre-revenue and has secured non-dilutive grant funding, including a SMART Grant from Innovate UK in 2024, to advance its platform and pipeline.

Inflammatory DiseasesInfectious DiseasesNeurologyPsychiatry

Technology Platform

PEPSMOL© - a proprietary platform designed to create 'synthetic biologics' that blend properties of small molecules and biologics to target hard-to-drug G protein-coupled receptors (GPCRs).

Opportunities

The PEPSMOL© platform offers a unique opportunity to unlock a large class of previously 'undruggable' GPCR targets, opening new therapeutic avenues across multiple disease areas.
Successful validation in severe asthma could lead to lucrative partnerships with large pharma companies seeking novel inflammatory disease pipelines.
The focus on high-burden, unmet needs like malaria and Alzheimer's aligns with significant global health priorities and market demand.

Risk Factors

The company faces high technical risk as its novel PEPSMOL© platform is unproven and must demonstrate it can reliably generate drug candidates.
Financial risk is significant, requiring substantial future capital raises to advance programs, which may dilute existing shareholders.
Intense competition from larger biopharma firms pursuing similar targets and modalities presents a key commercial and scientific challenge.

Competitive Landscape

Keltic Pharma competes in the crowded field of GPCR-targeted drug discovery, facing competition from large pharma and numerous biotechs using modalities like antibodies, peptides, and other novel scaffolds. In severe asthma, it competes against established biologic drugs (e.g., anti-IL-5, anti-IgE) and other novel mechanisms. Its differentiation hinges on the unique 'synthetic biologic' approach of PEPSMOL© to access challenging GPCR targets.

More companies in Small Molecule Drugs →More companies in Ireland →